30 related articles for article (PubMed ID: 38720543)
21. Evidence available on the use of the selective β3-adrenoceptor agonist mirabegron for the treatment of overactive bladder.
Angulo JC; Khullar V; Nitti VW; Siddiqui E
Actas Urol Esp; 2013; 37(10):640-51. PubMed ID: 23850394
[TBL] [Abstract][Full Text] [Related]
22. Mirabegron: A Review in Overactive Bladder Syndrome.
Deeks ED
Drugs; 2018 Jun; 78(8):833-844. PubMed ID: 29869204
[TBL] [Abstract][Full Text] [Related]
23. Plain language summary of safety and symptom improvement with vibegron in people with overactive bladder: results from the EMPOWUR study.
Staskin D; Frankel J; Gregg SG; Varano S; Owens-Grillo J
J Comp Eff Res; 2023 Sep; 12(9):CER. PubMed ID: 37586057
[TBL] [Abstract][Full Text] [Related]
24. Evaluating vibegron for the treatment of overactive bladder.
Rechberger T; Wróbel A
Expert Opin Pharmacother; 2021 Jan; 22(1):9-17. PubMed ID: 32993398
[TBL] [Abstract][Full Text] [Related]
25. Comparative analysis of real-world adherence and persistence patterns with vibegron, mirabegron, and anticholinergics in patients with overactive bladder: A retrospective claims study.
Chastek B; Carrera A; Landis C; Snyder D; Abedinzadeh L; Bancroft T; Nesheim J; Kennelly M; Staskin D
Neurourol Urodyn; 2024 May; ():. PubMed ID: 38720543
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of vibegron compared with mirabegron for overactive bladder: A systematic review and network meta-analysis.
He W; Zhang Y; Huang G; Tian Y; Sun Q; Liu X
Low Urin Tract Symptoms; 2023 May; 15(3):80-88. PubMed ID: 36863312
[TBL] [Abstract][Full Text] [Related]
27. An Evaluation of the Efficacy and Safety of Vibegron in the Treatment of Overactive Bladder.
Frankel J; Staskin D; Varano S; Kennelly MJ; Jankowich RA; Haag-Molkenteller C
Ther Clin Risk Manag; 2022; 18():171-182. PubMed ID: 35264853
[TBL] [Abstract][Full Text] [Related]
28. Mirabegron: β3-adrenergic receptor agonist for the treatment of overactive bladder.
Bridgeman MB; Friia NJ; Taft C; Shah M
Ann Pharmacother; 2013; 47(7-8):1029-38. PubMed ID: 23757386
[TBL] [Abstract][Full Text] [Related]
29. Clinical Utility of β
Krhut J; Skugarevská B; Míka D; Lund L; Zvara P
Res Rep Urol; 2022; 14():167-175. PubMed ID: 35502186
[TBL] [Abstract][Full Text] [Related]
30. [Efficacy and safety of available therapies in the management of idiopathic overactive bladder: A systematic review of the literature].
Moyson J; Legrand F; Vanden Bossche M; Quackels T; Roumeguère T
Prog Urol; 2017 Mar; 27(4):203-228. PubMed ID: 28228331
[TBL] [Abstract][Full Text] [Related]
[Previous] [New Search]
